Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Secondary Hypogonadism
Interventions
DRUG

Androxal

12.5 mg once daily

DRUG

Androxal

25 mg once daily

Trial Locations (18)

21285

The Center for Sexual Medicine at Sheppard Pratt, Baltimore

32308

Southeastern Research Group, Inc., Tallahassee

35235

Alabama Clinical Therapeutics, LLC, Birmingham

35801

Medial Affiliated Research Center, Inc., Huntsville

37203

Medical Research Associates of Nashville, Nashville

42431

Commonweatlh Biomedical Research, Madisonville

46825

Northeast Indiana Research, LLC, Fort Wayne

48152

Office of Keith Pierce, MD, Livonia

78229

Urology San Antonio Research, PA, San Antonio

84107

Salt Lake Research, Salt Lake City

89109

Office of Michael Mall, MD, Las Vegas

89144

Office of Stephen Miller, MD, Las Vegas

90502

Harbor-UCLA Medical Center, Torrance

92691

Prime-Care Clinical Research, Mission Viejo

95608

Northern California Research Corp, Carmichael

06708

Chase Medical Research, LLC, Waterbury

07601

Advanced Biomedical Research, Inc., Hackensack

08648

Office of Gary S. Karlin, MD, Lawrenceville

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01067365 - Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism | Biotech Hunter | Biotech Hunter